Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.13
NAS:ATRC's Cash-to-Debt is ranked lower than
56% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. NAS:ATRC: 1.13 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ATRC' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.13  Med: 9.56 Max: No Debt
Current: 1.13
Equity-to-Asset 0.61
NAS:ATRC's Equity-to-Asset is ranked higher than
57% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. NAS:ATRC: 0.61 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ATRC' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.15  Med: 0.66 Max: 0.97
Current: 0.61
-2.15
0.97
Piotroski F-Score: 4
Altman Z-Score: 3.29
Beneish M-Score: -2.88
WACC vs ROIC
3.85%
-18.43%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -20.07
NAS:ATRC's Operating Margin % is ranked lower than
75% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.86 vs. NAS:ATRC: -20.07 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ATRC' s Operating Margin % Range Over the Past 10 Years
Min: -28.44  Med: -17.57 Max: -5.41
Current: -20.07
-28.44
-5.41
Net Margin % -21.49
NAS:ATRC's Net Margin % is ranked lower than
75% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.79 vs. NAS:ATRC: -21.49 )
Ranked among companies with meaningful Net Margin % only.
NAS:ATRC' s Net Margin % Range Over the Past 10 Years
Min: -30.25  Med: -16.75 Max: -6.43
Current: -21.49
-30.25
-6.43
ROE % -18.80
NAS:ATRC's ROE % is ranked lower than
71% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. NAS:ATRC: -18.80 )
Ranked among companies with meaningful ROE % only.
NAS:ATRC' s ROE % Range Over the Past 10 Years
Min: -71.39  Med: -29.03 Max: -15.8
Current: -18.8
-71.39
-15.8
ROA % -12.15
NAS:ATRC's ROA % is ranked lower than
69% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.23 vs. NAS:ATRC: -12.15 )
Ranked among companies with meaningful ROA % only.
NAS:ATRC' s ROA % Range Over the Past 10 Years
Min: -42.11  Med: -16.02 Max: -11.04
Current: -12.15
-42.11
-11.04
ROC (Joel Greenblatt) % -68.35
NAS:ATRC's ROC (Joel Greenblatt) % is ranked lower than
74% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. NAS:ATRC: -68.35 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ATRC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -162.93  Med: -90.84 Max: -30.62
Current: -68.35
-162.93
-30.62
3-Year Revenue Growth Rate 7.00
NAS:ATRC's 3-Year Revenue Growth Rate is ranked higher than
59% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. NAS:ATRC: 7.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ATRC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -29.9  Med: 2.2 Max: 884
Current: 7
-29.9
884
3-Year EBITDA Growth Rate 17.40
NAS:ATRC's 3-Year EBITDA Growth Rate is ranked higher than
76% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. NAS:ATRC: 17.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ATRC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -63.9  Med: -17.2 Max: 129.3
Current: 17.4
-63.9
129.3
3-Year EPS without NRI Growth Rate 23.30
NAS:ATRC's 3-Year EPS without NRI Growth Rate is ranked higher than
79% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. NAS:ATRC: 23.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ATRC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -45.4  Med: -21.4 Max: 36.3
Current: 23.3
-45.4
36.3
GuruFocus has detected 3 Warning Signs with AtriCure Inc $NAS:ATRC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ATRC's 10-Y Financials

Financials (Next Earnings Date: 2017-05-04)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ATRC Guru Trades in Q1 2016

Jim Simons 114,800 sh (New)
Steven Cohen Sold Out
RS Investment Management 2,183,697 sh (-18.51%)
Chuck Royce 331,800 sh (-21.97%)
» More
Q2 2016

ATRC Guru Trades in Q2 2016

Chuck Royce 480,300 sh (+44.76%)
RS Investment Management 2,027,852 sh (-7.14%)
Jim Simons 90,600 sh (-21.08%)
» More
Q3 2016

ATRC Guru Trades in Q3 2016

Jim Simons 88,900 sh (-1.88%)
Chuck Royce 375,300 sh (-21.86%)
» More
Q4 2016

ATRC Guru Trades in Q4 2016

Paul Tudor Jones 12,903 sh (New)
Chuck Royce 329,300 sh (-12.26%)
Jim Simons 57,200 sh (-35.66%)
» More
» Details

Insider Trades

Latest Guru Trades with ATRC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:OTCPK:NNCSF, NAS:OSUR, NAS:ELGX, NAS:IRTC, NAS:ANGO, NAS:LMNX, NAS:LMAT, NAS:MLAB, NAS:ATRS, OTCPK:GMDTF, NAS:ATRI, AMEX:CRHM, NAS:STAA, NAS:NVCR, NAS:PLSE, NAS:ENTL, NAS:CFMS, NAS:UTMD, NAS:DSCI, NAS:SIEN » details
Traded in other countries:A5I.Germany,
Headquarter Location:USA
AtriCure Inc is a medical device company. It develops, manufactures and sells cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue.

AtriCure Inc was incorporated in the State of Delaware as AtriCure, Inc. on October 31, 2000. It is a medical device company and engaged in developing, manufacturing and selling cardiac surgical ablation systems designed to create precise lesions, in cardiac, or heart, tissue for the treatment of atrial fibrillation, and systems for the exclusion of the left atrial appendage. It has two primary product lines for the ablation of cardiac tissue. Its primary product line for the ablation of cardiac tissue is the AtriCure Synergy Ablation System ('Synergy System'), a bipolar ablation clamp system and related radiofrequency ('RF') ablation devices. It also offers a cryoablation product line, which features reusable and disposable cryoablation devices. Additionally, the Company offers the AtriClip Gillinov-Cosgrove Left Atrial Appendage System ('AtriClip System'), which is designed to safely and effectively exclude the left atrial appendage. Its products are utilized by cardiothoracic surgeons during concomitant open-heart surgical procedures and also during sole-therapy minimally invasive cardiac ablation procedures. During a concomitant open procedure, the surgeon ablates cardiac tissue and/or excludes the left atrial appendage, secondary, or concomitant, to a primary cardiac procedure such as a valve or coronary bypass. Additionally, cardiothoracic surgeons have adopted its products as a treatment alternative for AF patients who may be candidates for sole-therapy minimally invasive surgical procedures. Its Synergy System, which includes its Isolator Synergy clamps, a radiofrequency generator and related switchbox, is cleared by the FDA, for the treatment of patients with persistent and long-standing persistent AF during open-heart concomitant coronary artery bypass grafting and/or valve replacement or repair procedures. In the United States it primarily sells its products to medical centers through its direct sales force. AtriCure Europe, B.V., its wholly-owned subsidiary incorporated and based in the Netherlands, markets and sells its products throughout Europe, the Middle East and Africa, or EMEA, primarily through distributors, while in certain markets, such as Germany and the Benelux region, it sell directly to medical centers. Additionally, it sells its products to other international distributors, mainly in Asia, South America and Canada. The Company's competitors include Biosense Webster, Inc. (a subsidiary of Johnson & Johnson), St. Jude Medical, Inc., and Medtronic, Inc. Its products are medical devices and are subject to regulation by the FDA, as well as other federal and state regulatory bodies in the United States and comparable authorities in other countries.

Ratios

vs
industry
vs
history
PB Ratio 4.06
ATRC's PB Ratio is ranked lower than
54% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.56 vs. ATRC: 4.06 )
Ranked among companies with meaningful PB Ratio only.
ATRC' s PB Ratio Range Over the Past 10 Years
Min: 0.64  Med: 4.64 Max: 14.17
Current: 4.06
0.64
14.17
PS Ratio 4.17
ATRC's PS Ratio is ranked lower than
57% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. ATRC: 4.17 )
Ranked among companies with meaningful PS Ratio only.
ATRC' s PS Ratio Range Over the Past 10 Years
Min: 0.27  Med: 2.83 Max: 6.31
Current: 4.17
0.27
6.31
EV-to-EBIT -21.93
ATRC's EV-to-EBIT is ranked lower than
99.99% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.30 vs. ATRC: -21.93 )
Ranked among companies with meaningful EV-to-EBIT only.
ATRC' s EV-to-EBIT Range Over the Past 10 Years
Min: -99.5  Med: -17.55 Max: -0.5
Current: -21.93
-99.5
-0.5
EV-to-EBITDA -31.12
ATRC's EV-to-EBITDA is ranked lower than
99.99% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.15 vs. ATRC: -31.12 )
Ranked among companies with meaningful EV-to-EBITDA only.
ATRC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1617.5  Med: -22.35 Max: 1519.2
Current: -31.12
-1617.5
1519.2
Current Ratio 2.97
ATRC's Current Ratio is ranked higher than
64% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. ATRC: 2.97 )
Ranked among companies with meaningful Current Ratio only.
ATRC' s Current Ratio Range Over the Past 10 Years
Min: 1.96  Med: 2.97 Max: 7.25
Current: 2.97
1.96
7.25
Quick Ratio 2.36
ATRC's Quick Ratio is ranked higher than
67% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. ATRC: 2.36 )
Ranked among companies with meaningful Quick Ratio only.
ATRC' s Quick Ratio Range Over the Past 10 Years
Min: 1.58  Med: 2.36 Max: 6.88
Current: 2.36
1.58
6.88
Days Inventory 153.65
ATRC's Days Inventory is ranked lower than
67% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.79 vs. ATRC: 153.65 )
Ranked among companies with meaningful Days Inventory only.
ATRC' s Days Inventory Range Over the Past 10 Years
Min: 110.77  Med: 143.93 Max: 160.74
Current: 153.65
110.77
160.74
Days Sales Outstanding 49.64
ATRC's Days Sales Outstanding is ranked higher than
73% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.76 vs. ATRC: 49.64 )
Ranked among companies with meaningful Days Sales Outstanding only.
ATRC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.02  Med: 54.12 Max: 60.85
Current: 49.64
43.02
60.85
Days Payable 88.52
ATRC's Days Payable is ranked higher than
74% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.53 vs. ATRC: 88.52 )
Ranked among companies with meaningful Days Payable only.
ATRC' s Days Payable Range Over the Past 10 Years
Min: 87.74  Med: 115.72 Max: 167.47
Current: 88.52
87.74
167.47

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.80
ATRC's 3-Year Average Share Buyback Ratio is ranked lower than
75% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.20 vs. ATRC: -12.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ATRC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -97.7  Med: -12.8 Max: -1.2
Current: -12.8
-97.7
-1.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 61.75
ATRC's Price-to-Tangible-Book is ranked lower than
95% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.77 vs. ATRC: 61.75 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ATRC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.45  Med: 7.91 Max: 61.75
Current: 61.75
1.45
61.75
Price-to-Median-PS-Value 1.48
ATRC's Price-to-Median-PS-Value is ranked lower than
68% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. ATRC: 1.48 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ATRC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 0.98 Max: 1.72
Current: 1.48
0.2
1.72
Earnings Yield (Greenblatt) % -4.56
ATRC's Earnings Yield (Greenblatt) % is ranked lower than
79% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.18 vs. ATRC: -4.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ATRC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -7.1  Med: 0 Max: 0
Current: -4.56
-7.1
0

More Statistics

Revenue (TTM) (Mil) $155.1
EPS (TTM) $ -1.05
Beta0.24
Short Percentage of Float12.55%
52-Week Range $13.44 - 21.26
Shares Outstanding (Mil)33.95

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 173 191 212
EPS ($) -1.00 -0.74 -0.46
EPS without NRI ($) -1.00 -0.74 -0.46
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ATRC

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Amyris, AtriCure, 3D Systems Corporation and Cooper Tire & Rubber Compan Sep 10 2012 
AtriCure Inc. (ATRC) President and CEO and Director David J Drachman sells 40,671 Shares Feb 25 2011 
AtriCure Inc. Reports Operating Results (10-Q) Aug 10 2010 
AtriCure Inc. Reports Operating Results (10-Q) Nov 09 2009 
AtriCure Inc. Reports Operating Results (10-Q) Aug 10 2009 
AtriCure Inc. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide Apr 25 2017
AtriCure to Announce First Quarter 2017 Financial Results Apr 07 2017
ETFs with exposure to AtriCure, Inc. : April 5, 2017 Apr 05 2017
AtriCure founder exits amid board reset Mar 24 2017
AtriCure Names Two New Members to its Board of Directors Mar 21 2017
AtriCure, Inc. :ATRC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Mar 17 2017
AtriCure, Inc. :ATRC-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017
AtriCure Names National Principal Investigator for the CONVERGE IDE Clinical Trial Mar 14 2017
AtriCure to Present at the Needham & Company’s 16th Annual Healthcare Conference Mar 10 2017
AtriCure Announces hiring of Senior Vice President of Clinical, Regulatory, and Scientific Affairs Mar 06 2017
AtriCure reports 4Q loss Feb 28 2017
AtriCure Reports Fourth Quarter and Full Year 2016 Financial Results Feb 28 2017
AtriCure, Inc. breached its 50 day moving average in a Bullish Manner : ATRC-US : February 24, 2017 Feb 24 2017
CORRECTING and REPLACING AtriCure to Announce Fourth Quarter and Full Year 2016 Financial Results Feb 03 2017
AtriCure to Present at the Leerink Partners Global Healthcare Conference Jan 24 2017
AtriCure, Inc. – Value Analysis (NASDAQ:ATRC) : January 11, 2017 Jan 11 2017
AtriCure, Inc. breached its 50 day moving average in a Bearish Manner : ATRC-US : January 10, 2017 Jan 10 2017
AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2016 Jan 09 2017
Is Xenith Bankshares Inc (XBKS) Going To Burn These Hedge Funds? Dec 20 2016
AtriCure to Present at the 35th Annual JP Morgan Healthcare Conference Dec 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)